Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TNDM 
Tandem Diabetes Care Inc (TNDM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TNDM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $21.05
1 Year Target Price $21.05
| 6 | Strong Buy |
| 4 | Buy |
| 10 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.65% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.03B USD | Price to earnings Ratio - | 1Y Target Price 21.05 |
Price to earnings Ratio - | 1Y Target Price 21.05 | ||
Volume (30-day avg) 21 | Beta 1.49 | 52 Weeks Range 9.98 - 38.28 | Updated Date 10/18/2025 |
52 Weeks Range 9.98 - 38.28 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.51% | Operating Margin (TTM) -13.24% |
Management Effectiveness
Return on Assets (TTM) -6.41% | Return on Equity (TTM) -111.92% |
Valuation
Trailing PE - | Forward PE 1111.11 | Enterprise Value 1019482764 | Price to Sales(TTM) 1.03 |
Enterprise Value 1019482764 | Price to Sales(TTM) 1.03 | ||
Enterprise Value to Revenue 1.02 | Enterprise Value to EBITDA -10.72 | Shares Outstanding 67569471 | Shares Floating 61822687 |
Shares Outstanding 67569471 | Shares Floating 61822687 | ||
Percent Insiders 0.98 | Percent Institutions 120.44 |
Upturn AI SWOT
Tandem Diabetes Care Inc
Company Overview
History and Background
Tandem Diabetes Care, Inc. was founded in 2006. Initially known as Phlogos MedTech, the company focused on developing innovative solutions for diabetes management. A significant milestone was the development and launch of the t:slim insulin pump, which featured a touchscreen interface. Over time, Tandem has evolved into a leader in automated insulin delivery systems.
Core Business Areas
- Insulin Delivery Systems: Designs, develops, and commercializes innovative insulin delivery systems, including the t:slim X2 insulin pump and associated supplies.
- Software and Technology: Develops and offers software and technology solutions to enhance insulin delivery and diabetes management. The t:connect mobile app is part of this segment, allowing users to monitor and manage their therapy.
Leadership and Structure
Tandem Diabetes Care is led by CEO John Sheridan. The organizational structure includes departments such as Research and Development, Operations, Commercial, and Finance.
Top Products and Market Share
Key Offerings
- t:slim X2 Insulin Pump: The t:slim X2 insulin pump is Tandem's flagship product, featuring advanced control technology. It integrates with Dexcom G6 and G7 Continuous Glucose Monitoring (CGM) systems to automatically adjust insulin delivery. Estimated market share of the overall insulin pump market is approximately 25%. Competitors include Medtronic, Insulet, and Abbott (CGM integration).
- t:connect Mobile App: The t:connect mobile app allows users to wirelessly upload pump data to a secure cloud-based system. Competitors include similar connectivity solutions from Medtronic and other insulin pump manufacturers.
Market Dynamics
Industry Overview
The diabetes management industry is experiencing growth due to the increasing prevalence of diabetes globally and technological advancements in insulin delivery systems and CGMs. There is a growing trend towards automated insulin delivery (AID) systems.
Positioning
Tandem Diabetes Care is positioned as a leader in automated insulin delivery systems, particularly known for its integration with Dexcom CGMs. Its competitive advantage lies in its innovative technology, user-friendly design, and the advanced control algorithms.
Total Addressable Market (TAM)
The global insulin pump market is estimated to reach approximately $7.5 billion by 2028. Tandem Diabetes Care is well-positioned to capture a significant portion of this TAM through its advanced product offerings and market presence.
Upturn SWOT Analysis
Strengths
- Advanced technology in automated insulin delivery
- Integration with Dexcom CGM systems
- User-friendly design and interface
- Strong brand reputation in the diabetes community
Weaknesses
- Reliance on third-party CGM systems
- Higher price point compared to some competitors
- Limited product diversification beyond insulin pumps
- Dependence on regulatory approvals for product updates and new releases
Opportunities
- Expanding into new geographic markets
- Developing new features and functionalities for existing products
- Partnering with other healthcare providers and organizations
- Creating a closed loop solution with their own CGM
- Developing additional diabetes-related products and services
Threats
- Intense competition from established players
- Technological advancements by competitors
- Changes in reimbursement policies and healthcare regulations
- Potential cybersecurity risks associated with connected devices
Competitors and Market Share
Key Competitors
- MDT
- PODD
- ABT
Competitive Landscape
Tandem Diabetes Care faces competition from established players like Medtronic (MDT), Insulet (PODD), and Abbott (ABT). Tandem's advantage is its technology (Dexcom integration) and user-friendly design. Medtronic has a larger product portfolio. Insulet has the Omnipod (tubeless). Abbott has a new CGM (Libre) that could lead to a pump solution.
Growth Trajectory and Initiatives
Historical Growth: Tandem Diabetes Care has experienced significant revenue growth in recent years, driven by the increasing adoption of its t:slim X2 insulin pump and the related features.
Future Projections: Future growth projections vary depending on analyst estimates. Consensus estimates often anticipate continued revenue growth, driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include expanding partnerships with CGM manufacturers, introducing new software updates for its pumps, and expanding into new international markets.
Summary
Tandem Diabetes Care is a strong player in the automated insulin delivery market, driven by its advanced technology and integration with Dexcom CGMs. The company faces competition from larger, established players and is reliant on third-party CGM systems. Expansion into new markets and product diversification are key opportunities. Managing regulatory risks and cybersecurity threats is crucial for continued success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share and other data are estimates and may vary. Financial data is based on historical information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tandem Diabetes Care Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-11-14 | President, CEO & Director Mr. John F. Sheridan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2650 | Website https://www.tandemdiabetes.com |
Full time employees 2650 | Website https://www.tandemdiabetes.com | ||
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.